Navigation Links
CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G

own in previous studies that the dose of M6G required to provide analgesia immediately after surgery is three times that of morphine. In accordance with this, the M6G022 trial was designed such that M6G was available in a 3:1 ratio to morphine during the titration to comfort phase. Thereafter pain relief was provided using patient controlled analgesia (PCA) in a dose ratio of 2:1 (M6G:morphine). The secondary data announced today demonstrated again that in the initial phase after surgery the dose of M6G required to titrate patients to comfort was 3 times that required for morphine on a weight basis. However, during the prolonged PCA phase, the ratio was lower (0-24 hours 1.6:1; 24-48 hours 1.4:1). This shows that patients in the M6G group made less demands for pain relief after titration to comfort, as assessed by presses on the PCA button. These data support the hypothesis that M6G has a longer duration of analgesic action than morphine.

Sedation/safety

The M6G022 data shows that M6G patients experience lower levels of sedation compared to those on morphine for up to 48 hours. This is another advantage of M6G that has been indicated from previous clinical data and adds to the considerable package of potential benefits to patients and clinicians. The M6G patients also showed no adverse cardiovascular effects which again supports CeNeS claims that M6G has a very good safety profile.

Partnering strategy

There is a clear need for new drugs that can improve the quality of pain management currently given to patients by standard morphine regimens across the world and M6G is well positioned to address that market. Since the announcement of the successful data last week significant interest has been expressed by Pharma companies in reviewing the large M6G data package that CeNeS has assembled. CeNeS is confident that agreements can be finalised with partner(s) based on the existing set of clinical trial data. Concluding these deals will generate
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
3. CeNeS Pharmaceuticals Plc Announces Preliminary Results for The Year Ending 31 December 2006
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:9/2/2014)... 2, 2014  Based on its recent analysis ... Frost & Sullivan recognizes Novian Health, Inc. with ... for Technology Innovation Leadership. Novian Health has greatly ... tumors with its proprietary technology, Novilase ® ... accurate, and easy-to-control ultrasound-guided thermo ablation device that ...
(Date:9/2/2014)... DIEGO , Sept. 2, 2014 ResMed (NYSE: ... and Astral™ 150 devices in the United ... generation of portable, lightweight, and user-friendly life support ventilators. ... offer unparalleled mobility and ease of use for patients ... and other adult and childhood respiratory disorders. The U.S. ...
(Date:9/2/2014)... BEDFORD, Mass. , Sept. 2, 2014  Hologic, Inc. (NASDAQ: ... , President and Chief Executive Officer, will present at the ... City , New York on ... Interested parties are invited to listen to the live ... Hologic,s website at www.hologic.com/investors-overview . An archive of the ...
Breaking Medicine Technology:Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 2Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 3Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 4Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 5ResMed's Revolutionary Life Support Ventilation Platform -- Astral 100 and 150 Devices Now Available in the U.S. 2ResMed's Revolutionary Life Support Ventilation Platform -- Astral 100 and 150 Devices Now Available in the U.S. 3
... recognizes MedNet Solutions as the first QM Certified ... QualityMetric Incorporated announced today that MedNet Solutions, ... study management systems, is the first company to ... developed the QM Certified Scoring Partner program to ...
... Reports Significant Uptake of PlasmaBlade by U.S. Surgeons ... PEAK Surgical, Inc., a medical device company ... based on a proprietary technology, announced today several ... includes the PULSAR(R) Generator and the PEAK PlasmaBlade(TM) ...
Cached Medicine Technology:MedNet Solutions Certified to Score SF-12v2 Health Survey 2MedNet Solutions Certified to Score SF-12v2 Health Survey 3PEAK Surgical Announces Completion of First PRECISE Clinical Study, Receipt of Medical Design Excellence Award for PEAK(R) Surgery System and Achievement of Over 1,000 Surgeries Using PEAK PlasmaBlade(TM) 2PEAK Surgical Announces Completion of First PRECISE Clinical Study, Receipt of Medical Design Excellence Award for PEAK(R) Surgery System and Achievement of Over 1,000 Surgeries Using PEAK PlasmaBlade(TM) 3PEAK Surgical Announces Completion of First PRECISE Clinical Study, Receipt of Medical Design Excellence Award for PEAK(R) Surgery System and Achievement of Over 1,000 Surgeries Using PEAK PlasmaBlade(TM) 4
(Date:9/2/2014)... (PRWEB) September 02, 2014 As an industry ... in an industry and predict change. Fortunately for him, that ... him to identify markets that are eager for change — ... of the hearing aid market indicated it was ripe for ... consumer,” Sapio explained. As a result, he took matters into ...
(Date:9/2/2014)... is available in Spanish . ... found, through an experiment conducted on rats, that hyperproteic diets ... use for groups with bone disease problems, such as the ... that vegetal proteinin the case of the present study, soy ... the former increased the level of calcium in bones by ...
(Date:9/2/2014)... nurses in their work care for patients who are ... shown that many nurses in training feel unprepared and ... during end-of-life care. , Scientists from the Sahlgrenska Academy ... Gothenburg, the University of Skvde and the Ersta Skndal ... caring for dying patients, their ideas about how to ...
(Date:9/2/2014)... September 02, 2014 Catalent, the ... development solutions for drugs, biologics and consumer health ... strategic partner, Eli Lilly’s growth, it is to ... at its Philadelphia Clinical Supply Center of Excellence. ... capabilities in its clinical supply facility in Schorndorf, ...
(Date:9/2/2014)... Splashtop Inc. , the worldwide ... NTT DoCoMo to deliver Splashtop Business Lite ... Lite is included in NTT DoCoMo’s “Business Plus” program. ... that empower users to remote access their corporate computers ... 18 million users worldwide. Splashtop delivers the best ...
Breaking Medicine News(10 mins):Health News:David Sapio Launches Zounds Hearing Franchise 2Health News:Study conducted on rats suggests that hyperproteic diets can be beneficial for bones 2Health News:Many nurses unprepared to meet dying patients 2Health News:Catalent Supports Eli Lilly's Growing Global Clinical Trials Needs with New Investment in Automated Packaging Solutions 2Health News:Splashtop and NTT DoCoMo Partner to Deliver “Splashtop Business Lite” Secure Remote Access Solution to Business Customers 2
... affect heart despite symptom relief, experts say , , MONDAY, ... longer than they did 40 years ago, but not if ... the Mayo Clinic. , "When you look at persons with ... benefits over the last several decades of improved survival the ...
... for colorectal cancer screening, nearly two-thirds of screening colonoscopies ... in the October issue of the journal Gastroenterology, Thomas ... University School of Medicine and a Regenstrief Institute, Inc. ... who is at risk for colorectal cancer as well ...
... cancer who arent eligible for standard treatment is under ... unfortunate reality is that kidney problems often result from ... cisplatin and gemcitabine, says Dr. Teresa A. Coleman, hematologist-oncologist ... II study at about 120 sites in North America, ...
... Va., Oct. 29 CEL-SCI Corporation,(Amex: CVM ) ... of cancer immunotherapies on its new website. The link ... home page at http://www.cel-sci.com . Geert ... minds of many represents the future of cancer therapy. ...
... - Halogen Software Inc., the leading,provider of Web-based ... Vonage has selected Halogen eAppraisal with,Multi-Rater. Vonage, a ... a Web-based system to streamline the appraisal process ... top-notch services to its,customers. Vonage will be ...
... crisis in the developing world because of lack of ... His Royal Highness The Duke of York, Patron of ... , In the foreword to a special supplement ... The Duke of York says that this situation is ...
Cached Medicine News:Health News:Rheumatoid Arthritis Death Rate Unchanged 2Health News:Rheumatoid Arthritis Death Rate Unchanged 3Health News:1 size may not fit all 2Health News:New treatment option studied for bladder cancer 2Health News:New treatment option studied for bladder cancer 3Health News:Vonage Selects Halogen Software - New Solution to Streamline Employee Performance and Talent Management Across Organization 2Health News:British Royal highlights anesthesia crisis in the developing world 2
... magnifier is an easy to use, full ... so that the monitor (usually a ... magnifier and is not built in. This ... screen if desired in the future. Also ...
... Maxport is a powerful magnifier that helps the ... composed of a hand magnifier attached to a pair ... there is no need for a TV set. The ... magnify images on a book, a can of food, ...
... powerful, portable, hand-held digital magnifier designed for ... a computer mouse, Max connects directly to ... you to read newspapers, magazines, recipe cards ... any surface curved or straight. The optional ...
... Merlin is a superior full-color, auto-focus, ... vision user in mind, Merlin enables the ... black and white, high contrast positive or ... video magnifier, this optional feature enables the ...
Medicine Products: